Diagnosis and management of asthma in adults a review

Keyphrases

• Asthma 100%
• Asthma Management 100%
• Asthma Diagnosis 100%
• Inhaled Corticosteroids 80%
• Severe Asthma 40%
• Airway Obstruction 40%
• Biological Agents 40%
• Persistent Asthma 40%
• Long-acting β2-agonist 40%
• Short-acting 40%
• Quality of Life 20%
• Environmental Factors 20%
• Adult Population 20%
• Airway Hyperresponsiveness 20%
• Wheezing 20%
• Airway Inflammation 20%
• Clinically Significant 20%
• Standard of Care 20%
• Moderate-to-severe Asthma 20%
• Cough 20%
• Clinical Syndromes 20%
• Combination Therapy 20%
• Lower Respiratory Tract 20%
• Persistent Symptoms 20%
• Adult Patients 20%
• Spirometry 20%
• Additional Treatment 20%
• Controller 20%
• Dyspnea 20%
• Evidence-based Treatment 20%
• Daily Use 20%
• Omalizumab 20%
• Controller Medication 20%
• Tiotropium 20%
• Acute Symptoms 20%
• Long-acting Bronchodilators 20%
• Asthma Specialist 20%
• Mepolizumab 20%
• Reslizumab 20%
• Long-acting muscarinic Antagonist 20%
• Evidence-based Diagnosis 20%
• Injectable Biologics 20%
• Allergen Sensitivity 20%

Medicine and Dentistry

• Asthma 100%
• Asthma in Adults 100%
• Biological Product 37%
• Airway Obstruction 25%
• Severe Asthma 25%
• Combination Therapy 12%
• Environmental Factor 12%
• Drug Therapy 12%
• Quality of Life 12%
• Coughing 12%
• Clinical Syndrome 12%
• Wheeze 12%
• Patient with Asthma 12%
• Consultation 12%
• Dyspnea 12%
• Spirometry 12%
• Allergen 12%
• Bronchodilating Agent 12%
• Respiratory Tract Inflammation 12%
• Respiratory Tract Allergy 12%
• Lower Respiratory Tract 12%
• Omalizumab 12%
• Muscarinic Antagonist 12%
• Reslizumab 12%
• Mepolizumab 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Asthma 100%
• Biological Product 25%
• Airway Obstruction 16%
• Syndrome 8%
• Respiratory Tract Allergy 8%
• Respiratory Tract Inflammation 8%
• Wheezing 8%
• Combination Therapy 8%
• Respiratory Tract 8%
• Allergen 8%
• Bronchodilating Agent 8%
• Dyspnea 8%
• Coughing 8%
• Omalizumab 8%
• Muscarinic Receptor Blocking Agent 8%
• Mepolizumab 8%
• Reslizumab 8%